This randomized, double-blind, placebo-controlled, Phase 1b study evaluates the safety and
tolerability, and effects on cytokine and acute phase reactants of SP16, an anti-inflammatory
drug, in patients with pneumonia due to SARS-CoV-2 infection. The study will enroll up to 20
patients and each eligible patient will be randomized to receive either one of two doses of
SP16 (6 mg or 12 mg) or placebo by subcutaneous injection.